argen-x initiates a second pre-clinical development program in under 18 months from start of operations

argx-110 to target autoimmune, inflammation and oncology indications

17-May-2011 - Netherlands

arGEN-X announced that it has progressed ARGX-110, its second therapeutic candidate, into formal pre-clinical development in less than 18 months since the Company began its operations.

ARGX-110 is a completely novel, fully human antibody specific for an undisclosed, clinically validated cell surface receptor. The antibody has been shown in a series of pre-clinical models to modulate the function of this target with unrivalled potency. The qualities of ARGX-110 are a strong indicator of its potential in improving the treatment of autoimmune disorders, inflammation and cancer.

ARGX-110 has been selected from over 30 unique, potent, receptor-specific candidates generated from the SIMPLE Antibody™ platform. The ability of every antibody in the original panel to block the receptor highlights an unprecedented degree of intrinsic functionality in these antibodies. Further, every antibody has a different sequence composition, increasing the likelihood of covering every epitope on the target, including previously undiscovered functional epitopes. With such an unprecedented diversity of potent candidates available, arGEN-X intends to progress at least one back-up development candidate for the ARGX-110 program.

ARGX-110 has other important characteristics as a development candidate. Its sequence composition is 99% homologous to human and therefore requires no additional engineering for development as a therapeutic antibody. Further, expression studies indicate that ARGX-110 can be manufactured at consistently high quality and yield. arGEN-X anticipates filing an IND application for ARGX-110 in 2013.

ARGX-110 is one of five therapeutic programs under development at arGEN-X for the treatment of autoimmune disorders, inflammation and oncology, with two now in formal pre-clinical development. arGEN-X’ most advanced pre-clinical program is ARGX-109, a fully human antibody with unprecedented potency in neutralization of IL-6, an important pro-inflammatory cytokine in autoimmunity, inflammation and cancer.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous